162 related articles for article (PubMed ID: 10194841)
1. Liposome-mediated immunotherapy against respiratory influenza virus infection using double-stranded RNA poly ICLC.
Wong JP; Yang H; Nagata L; Kende M; Levy H; Schnell G; Blasetti K
Vaccine; 1999 Mar; 17(13-14):1788-95. PubMed ID: 10194841
[TBL] [Abstract][Full Text] [Related]
2. Activation of toll-like receptor signaling pathway for protection against influenza virus infection.
Wong JP; Christopher ME; Viswanathan S; Karpoff N; Dai X; Das D; Sun LQ; Wang M; Salazar AM
Vaccine; 2009 May; 27(25-26):3481-3. PubMed ID: 19200852
[TBL] [Abstract][Full Text] [Related]
3. Prophylaxis of acute respiratory virus infections using nucleic acid-based drugs.
Wong JP; Nagata LP; Christopher ME; Salazar AM; Dale RM
Vaccine; 2005 Mar; 23(17-18):2266-8. PubMed ID: 15755608
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic and therapeutic efficacies of poly(IC.LC) against respiratory influenza A virus infection in mice.
Wong JP; Saravolac EG; Sabuda D; Levy HB; Kende M
Antimicrob Agents Chemother; 1995 Nov; 39(11):2574-6. PubMed ID: 8585749
[TBL] [Abstract][Full Text] [Related]
5. Novel antiviral therapeutics to control foot-and-mouth disease.
Dias CC; Moraes MP; Weiss M; Diaz-San Segundo F; Perez-Martin E; Salazar AM; de los Santos T; Grubman MJ
J Interferon Cytokine Res; 2012 Oct; 32(10):462-73. PubMed ID: 22924938
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of poly-ICLC against Ebola-Zaire virus (EBOV) infection in mice and cynomolgus monkeys.
Kende M; Paragas J; Salazar AM
Antiviral Res; 2019 Mar; 163():179-184. PubMed ID: 30611774
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic, therapeutic and immune enhancement effect of liposome-encapsulated PolyICLC on highly pathogenic H5N1 influenza infection.
Li Y; Hu Y; Jin Y; Zhang G; Wong J; Sun LQ; Wang M
J Gene Med; 2011 Jan; 13(1):60-72. PubMed ID: 21259409
[TBL] [Abstract][Full Text] [Related]
8. Dose and regimen effects of poly ICLC, an interferon inducer, in a multi-dose bleomycin model of interstitial pulmonary fibrosis.
Wild JS; Hyde DM; Giri SN
Pharmacol Toxicol; 1994 Jul; 75(1):42-8. PubMed ID: 7526360
[TBL] [Abstract][Full Text] [Related]
9. Immunoprophylactic strategies against respiratory influenza virus infection.
Saravolac EG; Sabuda D; Crist C; Blasetti K; Schnell G; Yang H; Kende M; Levy HB; Wong JP
Vaccine; 2001 Mar; 19(17-19):2227-32. PubMed ID: 11257338
[TBL] [Abstract][Full Text] [Related]
10. Enhanced protection against respiratory influenza A infection in mice by liposome-encapsulated antibody.
Wong JP; Stadnyk LL; Saravolac EG
Immunology; 1994 Feb; 81(2):280-4. PubMed ID: 8157277
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic and therapeutic intranasal administration with an immunomodulator, Hiltonol
Kumaki Y; Salazar AM; Wandersee MK; Barnard DL
Antiviral Res; 2017 Mar; 139():1-12. PubMed ID: 27956136
[TBL] [Abstract][Full Text] [Related]
12. Enhanced therapeutic efficacy of poly(ICLC) and ribavirin combinations against Rift Valley fever virus infection in mice.
Kende M; Lupton HW; Rill WL; Levy HB; Canonico PG
Antimicrob Agents Chemother; 1987 Jul; 31(7):986-90. PubMed ID: 3662477
[TBL] [Abstract][Full Text] [Related]
13. Toxicity and response evaluation of the interferon inducer poly ICLC administered at low dose in advanced renal carcinoma and relapsed or refractory lymphoma: a report of two clinical trials of the Eastern Cooperative Oncology Group.
Giantonio BJ; Hochster H; Blum R; Wiernik PH; Hudes GR; Kirkwood J; Trump D; Oken MM
Invest New Drugs; 2001; 19(1):89-92. PubMed ID: 11291838
[TBL] [Abstract][Full Text] [Related]
14. Ranking of prophylactic efficacy of poly(ICLC) against Rift Valley fever virus infection in mice by incremental relative risk of death.
Kende M; Lupton HW; Rill WL; Gibbs P; Levy HB; Canonico PG
Antimicrob Agents Chemother; 1987 Aug; 31(8):1194-8. PubMed ID: 3631943
[TBL] [Abstract][Full Text] [Related]
15. Poly ICLC inhibits Plasmodium cynomolgi B malaria infection in rhesus monkeys.
Puri SK; Dutta GP; Levy HB; Maheshwari RK
J Interferon Cytokine Res; 1996 Jan; 16(1):49-52. PubMed ID: 8640451
[TBL] [Abstract][Full Text] [Related]
16. Activation of interferon response through toll-like receptor 3 impacts viral pathogenesis and pulmonary toll-like receptor expression during respiratory syncytial virus and influenza infections in the cotton rat Sigmodon hispidus model.
Boukhvalova MS; Sotomayor TB; Point RC; Pletneva LM; Prince GA; Blanco JC
J Interferon Cytokine Res; 2010 Apr; 30(4):229-42. PubMed ID: 20038196
[TBL] [Abstract][Full Text] [Related]
17. Poly-ICLC preconditioning protects the blood-brain barrier against ischemic injury in vitro through type I interferon signaling.
Gesuete R; Packard AE; Vartanian KB; Conrad VK; Stevens SL; Bahjat FR; Yang T; Stenzel-Poore MP
J Neurochem; 2012 Nov; 123 Suppl 2(Suppl 2):75-85. PubMed ID: 23050645
[TBL] [Abstract][Full Text] [Related]
18. Interferon protects mice against inhalation anthrax.
Walberg K; Baron S; Poast J; Schwartz B; Izotova L; Pestka S; Peterson JW
J Interferon Cytokine Res; 2008 Oct; 28(10):597-601. PubMed ID: 18778201
[TBL] [Abstract][Full Text] [Related]
19. Long-term treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: an open pilot study.
Salazar AM; Levy HB; Ondra S; Kende M; Scherokman B; Brown D; Mena H; Martin N; Schwab K; Donovan D; Dougherty D; Pulliam M; Ippolito M; Graves M; Brown H; Ommaya A
Neurosurgery; 1996 Jun; 38(6):1096-103; discussion 1103-4. PubMed ID: 8727138
[TBL] [Abstract][Full Text] [Related]
20. Enhanced induction of plasma interferon after subcutaneous administration in rabbits of poly ICLC with albumin.
Pessina GP; Muscettola M; Paulesu L; Bocci V
J Biol Regul Homeost Agents; 1989; 3(3):118-21. PubMed ID: 2483023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
